Shine-On BioMedical Co.,Ltd.
Shine-On BioMedical Co.,Ltd. research, develops, and manufactures anti-cancer related drug products. It also develops antibody anticancer drugs, such as exosome anti-cancer drugs, that includes SOB101 and SOB102; SOB201 for engineered multi-target exosomes; SOA101, a dual immune checkpoint T cell adapter antibody; and SOA201, a trispecific adapter immune cell antibody. Shine-On BioMedical Co.,Ltd… Read more
Shine-On BioMedical Co.,Ltd. (6926) - Total Assets
Latest total assets as of June 2025: NT$982.08 Million TWD
Based on the latest financial reports, Shine-On BioMedical Co.,Ltd. (6926) holds total assets worth NT$982.08 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shine-On BioMedical Co.,Ltd. - Total Assets Trend (2021–2024)
This chart illustrates how Shine-On BioMedical Co.,Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shine-On BioMedical Co.,Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Shine-On BioMedical Co.,Ltd.'s total assets of NT$982.08 Million consist of 99.3% current assets and 0.7% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 4.2% |
| Accounts Receivable | NT$700.00K | 0.1% |
| Inventory | NT$0.00 | 0.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$3.62 Million | 0.3% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Shine-On BioMedical Co.,Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shine-On BioMedical Co.,Ltd.'s current assets represent 99.3% of total assets in 2024, a decrease from 99.4% in 2021.
- Cash Position: Cash and equivalents constituted 4.2% of total assets in 2024, down from 90.5% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 0.3% of total assets.
Shine-On BioMedical Co.,Ltd. Competitors by Total Assets
Key competitors of Shine-On BioMedical Co.,Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Shine-On BioMedical Co.,Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Shine-On BioMedical Co.,Ltd. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Shine-On BioMedical Co.,Ltd. is currently not profitable relative to its asset base.
Shine-On BioMedical Co.,Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 115.08 | 56.04 | 330.89 |
| Quick Ratio | 115.08 | 56.04 | 330.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$964.77 Million | NT$ 1.08 Billion | NT$ 451.78 Million |
Shine-On BioMedical Co.,Ltd. - Advanced Valuation Insights
This section examines the relationship between Shine-On BioMedical Co.,Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.53 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -8.6% |
| Total Assets | NT$1.06 Billion |
| Market Capitalization | $33.28 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shine-On BioMedical Co.,Ltd.'s assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shine-On BioMedical Co.,Ltd.'s assets decreased by 8.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shine-On BioMedical Co.,Ltd. (2021–2024)
The table below shows the annual total assets of Shine-On BioMedical Co.,Ltd. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.06 Billion | -8.62% |
| 2023-12-31 | NT$1.16 Billion | -1.53% |
| 2022-12-31 | NT$1.18 Billion | +29.17% |
| 2021-12-31 | NT$911.82 Million | -- |